These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

10472 related items for PubMed ID: 1512464

  • 1. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
    Prezioso JA, FitzGerald GB, Wick MM.
    J Invest Dermatol; 1992 Sep; 99(3):289-93. PubMed ID: 1512464
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR.
    J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
    [Abstract] [Full Text] [Related]

  • 5. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.
    Biochem Pharmacol; 1987 Jan 01; 36(1):147-53. PubMed ID: 3801051
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
    Ongaro A, Pellati A, De Mattei M, De Terlizzi F, Rossi CR, Campana LG.
    Anticancer Drugs; 2015 Mar 01; 26(3):284-92. PubMed ID: 25514113
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo.
    Révész L, Edgren MR, Wainson AA.
    Int J Radiat Oncol Biol Phys; 1994 May 15; 29(2):403-6. PubMed ID: 8195041
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
    Smith AC, Liao JT, Page JG, Wientjes MG, Grieshaber CK.
    Cancer Res; 1989 Oct 01; 49(19):5385-91. PubMed ID: 2766304
    [Abstract] [Full Text] [Related]

  • 11. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF.
    J Clin Oncol; 1996 Jan 01; 14(1):249-56. PubMed ID: 8558205
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
    Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ.
    Cancer Res; 1995 Oct 15; 55(20):4507-11. PubMed ID: 7553617
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Markedly decreased expression of glutathione S-transferase pi gene in human cancer cell lines resistant to buthionine sulfoximine, an inhibitor of cellular glutathione synthesis.
    Yokomizo A, Kohno K, Wada M, Ono M, Morrow CS, Cowan KH, Kuwano M.
    J Biol Chem; 1995 Aug 18; 270(33):19451-7. PubMed ID: 7642628
    [Abstract] [Full Text] [Related]

  • 19. In vivo modulation of glutathione by buthionine sulfoximine: effect on marrow response to melphalan.
    Russo A, Tochner Z, Phillips T, Carmichael J, DeGraff W, Friedman N, Fisher J, Mitchell JB.
    Int J Radiat Oncol Biol Phys; 1986 Jul 18; 12(7):1187-9. PubMed ID: 3744938
    [Abstract] [Full Text] [Related]

  • 20. Overcoming tumor necrosis factor-alpha resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-alpha. Role of tumor necrosis factor-alpha mRNA down-regulation in tumor cell sensitization.
    Mizutani Y, Yoshida O.
    Cancer; 1994 Feb 01; 73(3):730-7. PubMed ID: 8299097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 524.